Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE: NIASPAN ANTITRUST LITIGATION
Case Number:
2:13-md-02460
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
-
December 21, 2021
DOJ Opioid Trial Team Tainted By Kirkland Ties, Ex-CEO Says
A U.S. Department of Justice lawyer who acquired "inside knowledge" about a drug distributor while at Kirkland & Ellis has seemingly been enlisted to exploit that knowledge in the opioid prosecution of the distributor's ex-CEO, and the DOJ's entire trial team should be disqualified, according to filings in New York federal court.
-
August 17, 2021
End-Payors Again Denied Cert. In Niaspan Pay-For-Delay MDL
A Pennsylvania federal judge once again declined to certify a class of end-payors in their suit alleging improper pay-for-delay settlements between AbbVie and Teva Pharmaceuticals Industries aimed at barring generic forms of cholesterol drug Niaspan, finding Tuesday they again failed to satisfy the ascertainability requirement.
-
June 03, 2020
No Cert. For End-Payors In Niaspan Pay-For-Delay MDL
A Pennsylvania federal judge declined Tuesday to certify a class of end-payor plaintiffs in their suit alleging improper pay-for-delay settlements between AbbVie and Teva Pharmaceuticals Industries aimed at barring generic forms of Niaspan, finding they failed to establish the ascertainability, predominance, or superiority requirements.
-
August 14, 2019
Teva, AbbVie Face Certified Class Over Niaspan Pay-For-Delay
A group of direct buyers of the cholesterol drug Niaspan scored a victory on Wednesday when a Pennsylvania federal judge approved their bid to move forward as a class with a pay-for-delay antitrust suit against Teva Pharmaceuticals Industries Ltd. and AbbVie Inc.
-
May 25, 2018
Buyers Can't Bar Testimony In Teva Pay-For-Delay Suit
A Pennsylvania federal judge has cleared Teva Pharmaceuticals Industries Ltd. to use deposition testimony in an antitrust class action over an alleged pay-for-delay scheme for generic versions of cholesterol drug Niaspan, ruling that the pharmaceutical giant had not weaponized information protected by attorney-client privilege.
-
July 10, 2015
AbbVie, Teva Can't Make Niaspan Buyers Give Up Sales Data
A Pennsylvania federal judge on Thursday denied AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. access to financial information from pharmacy wholesalers who are pursuing an antitrust class action against the drugmakers over an alleged pay-for-delay scheme involving generic versions of the cholesterol drug Niaspan.
-
May 07, 2015
Rite Aid Joins Pay-For-Delay MDL Over Generic Niaspan
A Pennsylvania federal judge folded Rite Aid Corp.'s pay-for-delay suit against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over Niaspan generics into related multidistrict litigation pending in the same court on Wednesday, marking the 19th antitrust action in the matter.
-
September 08, 2014
State Claims Trimmed From AbbVie, Teva Pay-for-Delay MDL
A Pennsylvania federal judge on Friday dismissed a slew of state law claims from mulitdistrict litigation against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over purported pay-for-delay settlements regarding generics of the cholesterol drug Niaspan but kept the plaintiffs' federal antitrust claims intact.
-
June 24, 2014
Niaspan Antitrust Injury Is 'Pure Speculation,' Judge Told
Plaintiffs pursuing class actions against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over allegedly improper pay-for-delay settlements aimed at barring generic versions of the cholesterol drug Niaspan from entering the market have failed to show they were injured by the deal, a Pennsylvania federal judge heard Tuesday.